Literature DB >> 24614836

Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT.

A G Vieira1, V A M Funke1, E C Nunes1, R Frare1, R Pasquini1.   

Abstract

Bronchiolitis obliterans (BO) is a severe pulmonary complication of allo-SCT. This study evaluated the incidence of BO in patients undergoing allo-SCT in Hospital Universitário da Universidade Federal do Paraná, risk factors for developing this complication and prognostic factors for those patients who developed this entity. The study included 1286 patients transplanted between 1979 and 2009 who survived for 100 days or more. We diagnosed 53 cases of BO. The cumulative incidence was 2.9% in 1 year and 3.7% in 3 years. Among patients with chronic GVHD, the cumulative incidence at the same intervals was 8.4% and 9.9%, respectively. The median time between transplantation and diagnosis of BO was 260 days (49-3877 days). In the multivariate analysis the risk factors for BO were female donor, older recipients and acute GVHD. The main prognostic factor was the severity of pulmonary impairment. Patients who developed BO earlier than 260 days had a worse prognosis than those who did so later. At least 80% of deaths were directly related to BO.

Entities:  

Mesh:

Year:  2014        PMID: 24614836     DOI: 10.1038/bmt.2014.25

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  18 in total

1.  Risk factors for airflow obstruction in recipients of bone marrow transplants.

Authors:  J G Clark; D A Schwartz; N Flournoy; K M Sullivan; S W Crawford; E D Thomas
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

2.  Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.

Authors:  Brandon K C Au; Margaret A Au; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-30       Impact factor: 5.742

3.  Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation.

Authors:  Ulrica Forslöw; Jonas Mattsson; Thomas Gustafsson; Mats Remberger
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-27       Impact factor: 5.742

4.  Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG.

Authors:  H K Holland; J R Wingard; W E Beschorner; R Saral; G W Santos
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

5.  Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation.

Authors:  C N Duncan; M R Buonanno; E V Barry; K Myers; D Peritz; L Lehmann
Journal:  Bone Marrow Transplant       Date:  2008-02-25       Impact factor: 5.483

6.  Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.

Authors:  Arkadiusz Z Dudek; Hemchandra Mahaseth; Todd E DeFor; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-10       Impact factor: 5.742

Review 7.  Bronchiolitis associated with bone marrow transplantation.

Authors:  S W Crawford; J G Clark
Journal:  Clin Chest Med       Date:  1993-12       Impact factor: 2.878

8.  A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation.

Authors:  A P Schwarer; J M Hughes; B Trotman-Dickenson; T Krausz; J M Goldman
Journal:  Transplantation       Date:  1992-12       Impact factor: 4.939

9.  Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation.

Authors:  D J Curtis; A Smale; F Thien; A P Schwarer; J Szer
Journal:  Bone Marrow Transplant       Date:  1995-07       Impact factor: 5.483

Review 10.  Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.

Authors:  G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

View more
  11 in total

1.  A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.

Authors:  Sabarinath Venniyil Radhakrishnan; Gerhard C Hildebrandt
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

2.  Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Ajay Sheshadri; Amin Alousi; Lara Bashoura; Karen Stolar; Shiva Baghaie; Muhammad H Arain; Laila Noor; Amulya Balagani; Akash Jain; David Blanco; Abel Ortiz; Susan K Peterson; Renee Langhals; Michael Taylor; Alex Stenzler; Rohtesh S Mehta; Uday R Popat; Chitra Hosing; Gabriela Rondon; Fan Shen; Liang Li; Guang-Shing Cheng; David E Ost; Richard E Champlin; Burton F Dickey
Journal:  Ann Am Thorac Soc       Date:  2020-10

3.  Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Authors:  Anne Bergeron; Sylvie Chevret; Angela Granata; Patrice Chevallier; Laure Vincent; Anne Huynh; Reza Tabrizi; Hélène Labussiere-Wallet; Marc Bernard; Sylvain Chantepie; Jacques-Olivier Bay; Anne Thiebaut-Bertrand; Sylvain Thepot; Nathalie Contentin; Luc-Matthieu Fornecker; Natacha Maillard; Karine Risso; Ana Berceanu; Didier Blaise; Regis Peffault de La Tour; Jason W Chien; Valérie Coiteux; Gérard Socié
Journal:  JAMA       Date:  2017-08-08       Impact factor: 56.272

4.  Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Ajay Sheshadri; Roy F Chemaly; Amin M Alousi; Pankil K Shah; Gabriela Rondon; Lara Bashoura; Joumana Kmeid; Jacques Azzi; David W Blanco; Maryam Kaous; Burton F Dickey; Richard E Champlin; Dimpy P Shah
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-03       Impact factor: 5.742

Review 5.  Airway disease in hematologic malignancies.

Authors:  Ricardo J José; Burton F Dickey; Ajay Sheshadri
Journal:  Expert Rev Respir Med       Date:  2022-02-21       Impact factor: 4.300

6.  Late-Onset, Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Cohort Study of Long-Term Survivors.

Authors:  Ole Henrik Myrdal; Trond Mogens Aaløkken; Phoi Phoi Diep; Ellen Ruud; Lorentz Brinch; Kristian Fosså; Henrik Mangseth; Johny Kongerud; Liv Ingunn Sikkeland; May B Lund
Journal:  Respiration       Date:  2021-12-22       Impact factor: 3.966

7.  Efficacy and safety of high-dose budesonide/formoterol in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplant.

Authors:  Kyung Hoon Kim; Jongmin Lee; Hee-Je Kim; Seok Lee; Yoo-Jin Kim; Jong Hyuk Lee; Chin Kook Rhee
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

8.  Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability.

Authors:  Ajay Sheshadri; Sukh Makhnoon; Amin M Alousi; Lara Bashoura; Rene Andrade; Christopher J Miller; Karen R Stolar; Muhammad Hasan Arain; Laila Noor; Amulya Balagani; Akash Jain; David Blanco; Abel Ortiz; Michael S Taylor; Alex Stenzler; Rohtesh Mehta; Uday R Popat; Chitra Hosing; David E Ost; Richard E Champlin; Burton F Dickey; Susan K Peterson
Journal:  JMIR Form Res       Date:  2022-02-07

9.  The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States.

Authors:  Naomi C Sacks; Bridget E Healey; Sajjad Raza; Philip L Cyr; Gerhard Boerner; Ajay Sheshadri
Journal:  Blood Adv       Date:  2022-03-08

10.  Association between chronic bacterial airway infection and prognosis of bronchiolitis obliterans syndrome after hematopoietic cell transplantation.

Authors:  Makiko Yomota; Noriyo Yanagawa; Fumikazu Sakai; Yuta Yamada; Noritaka Sekiya; Kazuteru Ohashi; Tatsuru Okamura
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.